First Time Loading...
A

Ambrx Biopharma Inc
NYSE:AMAM

Watchlist Manager
Ambrx Biopharma Inc
NYSE:AMAM
Watchlist
Price: 28 USD 0.07% Market Closed
Updated: May 5, 2024

Ambrx Biopharma Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ambrx Biopharma Inc
Cash from Financing Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
Ambrx Biopharma Inc
NYSE:AMAM
Cash from Financing Activities
$930k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$17.2B
CAGR 3-Years
-14%
CAGR 5-Years
-4%
CAGR 10-Years
-17%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$5.1B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
$21B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
23%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$562.2m
CAGR 3-Years
-4%
CAGR 5-Years
-51%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.8B
CAGR 3-Years
3%
CAGR 5-Years
-88%
CAGR 10-Years
N/A

See Also

What is Ambrx Biopharma Inc's Cash from Financing Activities?
Cash from Financing Activities
930k USD

Based on the financial report for Dec 31, 2022, Ambrx Biopharma Inc's Cash from Financing Activities amounts to 930k USD.

What is Ambrx Biopharma Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 1Y
-99%

Over the last year, the Cash from Financing Activities growth was -99%.